4-Methyl-6-(2-methylimidazol-1-yl)-5-nitro-2-propoxypyrimidine

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 4-Methyl-6-(2-methylimidazol-1-yl)-5-nitro-2-propoxypyrimidine
• 化学式: C12H15N5O3
• 分子量: 277.28
• InChiKey: JCLINZYVWUVNGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  98.6
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Methods of using pyrimidine-based antiviral agents
  申请人：Tularik Inc.

  公开号：US20030130264A1

  公开（公告）日：2003-07-10

  The invention provides novel methods of using substituted pyrimidine compounds and compositions for the treatment or prevention of diseases associated with CMV infection. In particular, the present invention provides methods for the treatment or prevention of cardiovascular diseases and organ transplant rejection.

  该发明提供了使用取代嘧啶化合物和组合物治疗或预防与CMV感染相关疾病的新方法。具体来说，本发明提供了治疗或预防心血管疾病和器官移植排斥的方法。
• Novel pyrimidine carboxamides
  申请人：Tadiparthi Ravikumar

  公开号：US20070072876A1

  公开（公告）日：2007-03-29

  The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly relates to novel pyrimidine carboxamides of the general formula (I). Also included is a method of prophylaxis or treatment of a pain disorder, immunological diseases, inflammation, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of a compound of formula (I) as described above.

  本发明涉及一般式(I)的新化合物，它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、水合物、溶剂化物、药学上可接受的盐和组合物、它们的代谢物和前药。本发明更特别地涉及一般式(I)的新嘧啶羧酰胺。还包括一种预防或治疗疼痛障碍、免疫性疾病、炎症、类风湿性关节炎、骨质疏松症、多发性骨髓瘤、葡萄膜炎、急性和慢性髓性白血病、缺血性心脏病、动脉硬化、癌症、缺血性细胞损伤、胰岛素β细胞破坏、骨关节炎、类风湿脊柱炎、痛风性关节炎、炎症性肠病、成人呼吸窘迫综合症(ARDS)、牛皮癣、克罗恩病、过敏性鼻炎、溃疡性结肠炎、过敏性休克、接触性皮炎、肌肉退化、消瘦症、哮喘、骨吸收疾病、缺血再灌注损伤、脑外伤、多发性硬化症、败血症、脓毒性休克、毒性休克综合症、发热和肌痛等哺乳动物感染的方法，包括给予上述一般式(I)化合物的有效量。
• Pyrimidine derivatives
  申请人：Tularik Inc.

  公开号：US20010018436A1

  公开（公告）日：2001-08-30

  Compounds and compositions are provided which are useful for the treatment of viral infections, particularly human Cytomegalovirus infection. The compounds include novel pyrimidine-based derivatives.

  提供了用于治疗病毒感染的化合物和组合物，特别是人类巨细胞病毒感染的化合物。这些化合物包括新型嘧啶基衍生物。
• US6200977B1
  申请人：——

  公开号：US6200977B1

  公开（公告）日：2001-03-13
• US6528513B2
  申请人：——

  公开号：US6528513B2

  公开（公告）日：2003-03-04